

# ARCHIVOS DE Bronconeumología



www.archbronconeumol.org

## Original Article Small Airway Dysfunction in Children With Controlled Asthma<sup>☆</sup>



Garazi Azaldegi,<sup>a</sup> Javier Korta,<sup>a,b</sup> Olaia Sardón,<sup>a,b</sup> Paula Corcuera,<sup>a</sup> Eduardo G. Pérez-Yarza<sup>a,b,</sup>

<sup>a</sup> Sección de Neumología Infantil, Hospital Universitario Donostia, San Sebastián, Spain

<sup>b</sup> Departamento de Pediatría, Universidad del País Vasco (UPV/EHU), San Sebastián, Spain

<sup>c</sup> Centro de Investigación Biomédica en Red, Enfermedades Respiratorias (CIBERES), San Sebastián, Spain

## A R T I C L E I N F O

## ABSTRACT

Article history: Received 22 June 2018 Accepted 29 August 2018 Available online 11 March 2019

Keywords: Small airway Asthma Children *Introduction:* Asthma is characterized by chronic inflammation of the central and distal airways. The aim of this study was to assess the small airway (SA) of children with moderate-severe asthma with normal FEV1.

*Methods:* This was an open-label, prospective, observational, cross-sectional study with consecutive inclusion of patients with moderate-severe asthma, receiving standard clinical treatment, with normal baseline FEV<sub>1</sub>. We determined multiflow FEno (CAno), oscillatory resistance and reactance (R5–R20, X5), forced spirometry (FEV1, FEF<sub>25-75</sub>), total body plethysmography (RV/TLC) and bronchodilation test. SA involvement was defined as: CAno >4.5 ppb, R5–R20 >0.147 kPa/L/s, X5 <-0.18 kPa/L, FEF<sub>25-75</sub> <-1.65 *z*-score, RV/TLC >33%. Poor asthma control was defined as  $\leq$ 19 points on the ACT questionnaire or  $\leq$ 20 on the c-ACT.

*Results:* In a cohort of 100 cases, 76 had moderate asthma and 24 had severe asthma; 71 children were classified as poorly controlled and 29 were well-controlled. In total, 77.78% of the group with all the correct determinations (n=72) showed  $\geq$  1 altered SA parameter and 48.61%  $\geq$  2 parameters. There were no differences between well-controlled or poorly controlled cases.

*Conclusions:* Children with moderate-severe asthma, with normal FEV<sub>1</sub>, show a phenotype of dysfunctional SA. In our series, the evaluation of SA using the techniques described above did not provide information on disease control.

© 2018 SEPAR. Published by Elsevier España, S.L.U. All rights reserved.

## Disfunción de la pequeña vía aérea en niños con asma controlada

## RESUMEN

*Introducción:* El asma se caracteriza por una inflamación crónica de las vías respiratorias centrales y distales. El objetivo de este estudio ha sido evaluar la vía aérea pequeña (VAP) en niños con asma moderada y/o grave con FEV<sub>1</sub> normal.

*Métodos*: Estudio abierto, prospectivo, observacional y transversal con inclusión consecutiva de casos con asma moderada o grave, bajo tratamiento clínico habitual con FEV<sub>1</sub> basal normal. Se ha determinado la *FE*No a flujos múltiples (*CA*NO), resistencias y reactancia oscilatorias (R5-R20, X5), espirometría forzada (FEV<sub>1</sub>, FEF<sub>25-75</sub>), pletismografía corporal total (RV/TLC) y prueba de broncodilatación. La afectación de la VAP se definió por: *CA*NO > 4,5 ppb, R5-R20 > 0,147 kPa/L/s, X5 < -0,18 kPa/L, FEF<sub>25-75</sub> < -1,65 z-score, RV/TLC > 33%. El mal control de asma se definió por  $\leq 19$  puntos en el cuestionario ACT o  $\leq 20$  en c-ACT. *Resultados*: Cohorte de 100 casos, 76 con asma moderada y 24 con asma grave, 71 niños clasificados como mal controlados y 29 bien controlados. El 77,78% del grupo con todas las determinaciones correctas (n = 72) mostró  $\geq 1$  parámetro alterado de VAP y el 48,61%  $\geq 2$  parámetros. No hubo diferencias entre los casos bien y mal controlados.

\* Corresponding author.

E-mail address: gonpeya@icloud.com (E.G. Pérez-Yarza).

1579-2129/© 2018 SEPAR. Published by Elsevier España, S.L.U. All rights reserved.

Palabras clave: Pequeña vía aérea Asma Niños

<sup>\*</sup> Please cite this article as: Azaldegi G, Korta J, Sardón O, Corcuera P, Pérez-Yarza EG. Disfunción de la pequeña vía aérea en niños con asma controlada. Arch Bronconeumol. 2019;55:208–213.

*Conclusiones:* Los niños con asma moderada y grave, con el FEV<sub>1</sub> preservado, muestran un fenotipo de VAP disfuncionante. En nuestra muestra, la evaluación de la VAP mediante las técnicas descritas, no aporta información sobre el control habitual de la enfermedad.

© 2018 SEPAR. Publicado por Elsevier España, S.L.U. Todos los derechos reservados.

### Introduction

Asthma is a disease characterized by chronic airway inflammation that affects the entire respiratory tract, from the central airways to the more peripheral areas.<sup>1</sup> Some researchers suggest that inflammation and airway remodeling of the small airways (SA) occurs in humans and experimental models,<sup>2</sup> and that this SA involvement is associated with increased asthma symptoms and worse disease control. In childhood, peak expiratory flow 25%-75% is considered to be an indirect marker of SA function.<sup>3</sup> Increased resistance and decreased reactance determined by oscillometry are associated with worse health status and poor disease control in children<sup>4</sup> and in adults.<sup>5</sup> Other studies suggest that mesoflow involvement is also associated with poorer disease control.<sup>6,7</sup> Air trapping, determined indirectly by body plethysmography, has been associated with more severe exacerbations,<sup>8</sup> more hospitalizations for asthma,<sup>9</sup> and with worse health-related quality of life.<sup>10</sup> Other authors have also reported that increased nitric oxide alveolar concentration (CAno) is associated with the presence of symptoms and worse asthma control in children.<sup>11</sup> SA dysfunction is seen in patients with severe asthma.<sup>12,13</sup>

The main objective of this study was to evaluate SA function in children with asthma in routine clinical practice using normal forced expiratory volume in 1 s (FEV<sub>1</sub>), to determine the potential usefulness of this parameter in asthma management.

## Methods

The study was approved by the Clinical Research Ethics Committee of our hospital. In all cases, informed consent was obtained from the parents (and from children over the age of 11 years) and permission for the use of data was given, in compliance with legal regulations.

This was a prospective, observational, cross-sectional study in patients aged between 7 and 15 years, diagnosed with asthma classified as moderate or severe according to GINA 2016,<sup>1</sup> requiring Step 3 treatment or higher (inhaled glucocorticoids in association with long-acting  $\beta_2$ -adrenergic agonists) for at least the previous 4 months, seen in the outpatient clinic of the pediatric respiratory department of a tertiary hospital. The recruitment period was from January 1 to June 30, 2015.

Exclusion criteria were:  $FEV_1$  lower than 80% of the predicted value, poor inhalation technique with core treatment, poor adherence (<80% of the prescribed doses),<sup>14</sup> an asthma exacerbation in the last 7 days, treated with oral glucocorticoids in the last 7 days, acute respiratory infection and/or fever, and inability to collaborate with lung function tests.

In the absence of data on the prevalence of SA dysfunction in children with moderate or severe asthma, a pilot study was carried out in the first 30 cases to estimate the sample size (23 had moderate asthma and 7 severe). No differences were observed between the groups. There was no association between the variables of measurement of resistances between 5 and 20 Hz (R5–R20), reactance at 5 Hz (X5), CAno, residual volume and total lung capacity ratio (RV/TLC) and forced expiratory flow between 25% and 75% of forced vital capacity (FEF<sub>25–75</sub>). With the cut-off points used, parameters for SA dysfunction were as follows CAno (n=4), R5–R20 (n=13), X5 (n=12), FEF<sub>25–75</sub> (n=3) and RV/TLC (n=6). Recruitment continued

until a sufficient theoretical sample size (n=100) was reached to meet the study objective.

In all cases, the fraction of exhaled nitric oxide was determined from a single breath and multiple flows (30, 150, and 250 ml/s), using the Eco Medics UNCCD 88 SP<sup>®</sup> chemiluminescence stationary analyzer with Denox 88 flow adaptors, to obtain CAno using the 2-compartment model and the equation of Tsoukias and George.<sup>15</sup> We then performed, in the following order, pulse oscillometry (PO) (MasterLab version 5.1, Viasys<sup>®</sup>, Wuerzburg, Germany), forced spirometry (MasterScreen v. 4.67, Viasys<sup>®</sup>, Germany), and total body plethysmography (MasterLab version 5.1, Viasys<sup>®</sup>, Wuerzburg, Germany). After these baseline tests, the bronchodilation (BD) test was performed, administering inhaled salbutamol (400  $\mu$ g) with a Volumatic<sup>®</sup> spacer and repeating PO, forced spirometry, and plethysmography 15 min later. All these techniques were performed according to the published recommendations.<sup>16–20</sup>

We used the reference values of Lechtenbörger et al.<sup>21</sup> for PO, Jaeger<sup>22</sup> for plethysmography resistances, and the equations proposed by Zapletal<sup>23</sup> for forced spirometry and plethysmography. The BD test was considered positive in case of FEV<sub>1</sub>  $\geq$ 12% compared to the previous value or  $\geq$ 9% compared to the predicted value.<sup>24</sup>

SA dysfunction was defined as CAno >4.5 ppb<sup>25</sup>; R5–R20 >0.147 kPa/L/s<sup>4</sup>; X5 <–0.18 kPa/L<sup>4</sup>; FEF<sub>25–75</sub> <65% predicted<sup>26</sup>; and/or RV/TLC >33%.<sup>27</sup>

We calculated the *z*-score corresponding to 65% of the predicted value of  $FEF_{25-75}$ , using logistic regression in the sample, which was (-1.65) the value used as the cut-off point.

All subjects completed the ACT asthma control questionnaire in Spanish for patients aged over 12 years<sup>28</sup> or the c-ACT pediatric version in the case of children under the age of 12 years.<sup>29</sup> Poor asthma control was defined as a score of  $\leq$ 19 points on the ACT questionnaire or  $\leq$ 20 on the c-ACT.

Data were processed using the Stata statistical package version  $14.1^{\text{(Stata Corp., TX, USA)}}$ , in a specifically designed database. A *P*<.05 was considered statistically significant. A descriptive analysis was performed of demographic and baseline characteristics, which included the number of observations, mean and standard deviation from the mean for continuous variables, and frequencies for categorical variables. Variables with non-normal distribution were expressed as median and range, and the analysis was carried out using non-parametric statistics (Kruskal–Wallis test). For continuous variables, the differences between the 2 groups were analyzed using Student's *t* test for independent samples and analysis of variance, and Pearson's chi-squared test or Fisher's exact test were used for categorical variables. We analyzed the correlation and degree of agreement of the different parameters that evaluate the SA using Spearman's correlation coefficient and Cohen's kappa coefficient.

## Results

A total of 139 cases were recruited consecutively from the outpatient clinic of the pediatric respiratory department. Thirtynine cases who met one or more of the exclusion criteria were excluded: 4 receiving bronchodilation; 1 permission not given; 11 non-collaborative for functional testing; 3 received treatment with oral glucocorticoids in the last 7 days; 3 had current respiratory infection; 8 current exacerbation; 6 poor treatment compliance; and 3 had FEV<sub>1</sub> less than 80% predicted.

#### Table 1

Mean Values of the Various Parameters Indicative of Airway Involvement in the Overall Group of Asthmatic Children and in Subgroups of Moderate Asthma and Severe Asthma.

| SA Parameters                           | Overall Group (n=100) | Moderate Asthma (n=76) | Severe Asthma (n=24) | $P^{\mathrm{a}}$ |
|---|-----------------------|------------------------|----------------------|------------------|
| CAno [ppb, median (range)]              | 1.45 (0-15)           | 0.6 (0-9.4)            | 1.15 (0-15)          | .57 <sup>b</sup> |
| R5-R20 (kPa/L/s, mean±SD)               | $0.14{\pm}0.11$       | 0.13±0.10              | $0.19{\pm}0.14$      | .02              |
| X5 (kPa/L/s, mean±SD)                   | $-0.19{\pm}0.91$      | $-0.19{\pm}0.08$       | $-0.22{\pm}0.12$     | .15              |
| FEF <sub>25-75</sub> (z-score, mean±SD) | $-0.76 \pm 1.22$      | $-0.68 \pm 1.13$       | $-1.02{\pm}1.50$     | .24              |
| RV/TLC (%, mean±SD)                     | $28.38 {\pm} 6.29$    | $28.34{\pm}6.37$       | $28.54{\pm}6.20$     | .89              |

CAno: alveolar concentration of nitric oxide; FEF<sub>25–75</sub>: forced expiratory flow between 25% and 75% of the forced vital capacity; R5–R20: resistance between 5 and 20 Hz; RV/TLC: residual volume/total lung capacity ratio; SA: small airways; SD: standard deviation; X5: resistance at 5 Hz; *z*-score: standardized variable to compare data.

<sup>a</sup> Analysis using Student's *t* test.

<sup>b</sup> Analysis using Kruskal–Wallis test.

#### Table 2

Mean Values of the Various Parameters Indicating Small Airway Involvement in the Overall Group of Asthmatic Children and in Subgroups of Moderate Asthma and Severe Asthma.

|                              |             | SA Involvement                 |    |                                |    |                               | Р                |
|------------------------------|-------------|--------------------------------|----|--------------------------------|----|-------------------------------|------------------|
|                              | Overall Gro | Overall Group ( <i>n</i> =100) |    | Moderate Asthma( <i>n</i> =76) |    | Severe Asthma ( <i>n</i> =24) |                  |
|                              | n           | %                              | n  | %                              | n  | %                             |                  |
| CAno ( <i>n</i> =72)         | 7           | 9.72                           | 4  | 5.26                           | 3  | 12.5                          | .37ª             |
| R5-R20(n=100)                | 49          | 49                             | 24 | 24                             | 15 | 15                            | .13 <sup>b</sup> |
| X5 (n=100)                   | 47          | 47                             | 33 | 33                             | 14 | 14                            | .20ª             |
| FEF <sub>25-75</sub> (n=100) | 26          | 26                             | 16 | 16                             | 10 | 10                            | .04 <sup>b</sup> |
| RV/TLC (n=100)               | 20          | 20                             | 16 | 16                             | 4  | 4                             | .77ª             |

CAno: alveolar concentration of nitric oxide; FEF<sub>25-75</sub>: forced expiratory flow between 25% and 75% of the forced vital capacity; R5–R20: resistance between 5 and 20 Hz; RV/TLC: residual volume/total lung capacity ratio; SA: small airways; X5: resistance at 5 Hz.

<sup>a</sup> Analysis using Fisher's exact test.

<sup>b</sup> Analysis using Pearson's chi-square test.

#### Table 3

Number of Parameters Indicating Abnormal Airway Involvement in the Overall Group of Asthmatic Children and in Subgroups of Moderate Asthma and Severe Asthma.

| No. of Abnormal Parameters | Overall Group (n=72) |       | Moderate Asthma ( <i>n</i> =53) |       | Severe Asthma | ( <i>n</i> =19) |
|----------------------------|----------------------|-------|---------------------------------|-------|---------------|-----------------|
|                            | Cases                | %     | Cases                           | %     | Cases         | %               |
| 0                          | 16                   | 22.22 | 14                              | 19.44 | 2             | 2.78            |
| 1                          | 21                   | 29.17 | 13                              | 18.06 | 8             | 11.11           |
| 2                          | 16                   | 22.22 | 13                              | 18.06 | 3             | 4.17            |
| 3                          | 13                   | 18.06 | 9                               | 12.5  | 4             | 5.56            |
| 4                          | 5                    | 6.94  | 4                               | 5.56  | 1             | 1.39            |
| 5                          | 1                    | 1.39  | 0                               | 0     | 1             | 1.39            |

Mean age of the 100 cases included was  $11.1\pm2.53$  years (range 7–15), with a predominance of males (*n*=67). A total of 76 cases were classified as moderate asthma and 24 as severe asthma; 71 cases were poorly controlled and 29 well-controlled, with no differences between groups of moderate and severe asthma (*P*=.12).

All cases (n=100) performed all the tests and presented all variables, except for 28 cases where the determinations of the fraction of exhaled nitric oxide did not follow the linear model. There were no significant differences between moderate asthma and severe asthma in non-dependent variables of SA in the nitric oxide, spirometry and plethysmography tests, except for PO: cases with severe asthma had higher R5 (P=.02) and Z5 (P=.02) values.

For the SA variables, cases of severe asthma showed higher R5–R20 values (P=.02) (Table 1). SA parameters indicated dysfunction at the rates shown in Table 2. There were no differences between moderate asthma and severe asthma, except in FEF<sub>25–75</sub>, which was more often abnormal in severe asthma (P=.04). Of the cases with complete, valid results (n=72), 77.78% presented 1 or more abnormal parameter and 48.61% had 2 or more; no significant differences were found between moderate asthma and severe asthma (P=.27) (Table 3).

We analyzed the relationship between the dependent SA variables. There was a moderate correlation between  $FEF_{25-75}$  and R5-R20 (r=-0.58) (Fig. 1), between  $FEF_{25-75}$  and X5 (r=0.57) (Fig. 2),




Fig. 1. Correlation between  $\mbox{FEF}_{25-75}$  and R5–R20 in the overall group of asthmatic children.

and between R5–R20 and X5 (r=–0.58) (Fig. 3). There was moderate agreement between R5–R20 and X5 ( $\kappa$ =0.44; P<.05) and low agreement between R5–R20 and FEF<sub>25–75</sub> ( $\kappa$ =0.29; P<.05), X5 and FEF<sub>25–75</sub> ( $\kappa$ =0.28; P=.00) and RV/TLC and FEF<sub>25–75</sub> ( $\kappa$ =0.27; P<.05).





Fig. 2. Correlation between  $\mbox{FEF}_{25-75}$  and X5 in the overall group of asthmatic children.



**Fig. 3.** Correlation between X5 and R5–R20 in the overall group of asthmatic children.

The BD test was positive in 19 cases. In this group, there were no differences between moderate asthma and severe asthma, nor among subgroups of good and poor control. Patients with a positive BD test positive obtained worse results than the group with a negative BD test (Table 4).

SA parameters were compared among groups with good and poor disease control, and no statistically significant differences were found in any of the variables (Table 5). Similarly, the sum of different abnormal parameters was not indicative of poorer disease control (*P*=.07).

Finally, the number of abnormal SA parameters was not associated with hospitalizations for asthma during the past 12 months (2 cases) (Fisher's exact test, *P*=.06).

## Discussion

This study included patients with  $FEV_1$  higher than 80% predicted value with the aim of assessing whether SA dysfunction could be the reason for not achieving complete disease control in patients with normal proximal airway function.

One of the main problems in analyzing and evaluating the degree of SA involvement is difficulty in accessing this region, and the different techniques used have their limitations. FEF<sub>25-75</sub> is one of the most commonly cited measurements of SA involvement, although its limitations are known. In the absence of expiratory airflow limitation, an increase in RV could be attributed to a premature closure of the SA, and given that the TLC does not usually change in asthma, SA involvement could manifest itself through an increase in the RV/TLC ratio, a marker of air trapping and pulmonary hyperinflation. In PO, the difference between total resistance and central resistance [R(5 Hz)-R(20 Hz)] corresponds to SA resistance, while pulmonary reactance measured at 5 Hz reflects the elastic properties, capacitance, and the degree of obstruction of the peripheral airways. Moreover, CAno is interpreted as a surrogate marker of inflammatory involvement of the SA.

One of the key findings of our study was that 77.78% of children with moderate and severe asthma who performed all SA tests (72 cases), treated with a combination of medium or high-dose ICS and 2  $\beta_2$ -adrenergic agonists, with normal FEV1 and a very low number of hospitalizations during the last year (2 cases), had at least 1 criterion for SA involvement, as also reported by Pisi et al.<sup>30</sup> and Wagner et al.<sup>31</sup> in asthma patients with normal FEV1 values. This finding, which we consider of interest, warrants the conduct of longitudinal studies to evaluate its significance in the management and good control of children with asthma.<sup>32</sup>

SA involvement was evidenced primarily by PO, by both R5–R20 (n=49) and X5 (n=47). However, FEF<sub>25–75</sub>, RV/TLC and CAno showed fewer abnormal results [n=26, n=20 and n=7 (9.72%), respectively], which indicates that the cut-off points used for the PO parameters might be either too sensitive to changes in the peripheral airways or not very specific.

In terms of CAno, the 2-compartmental model of nitric oxide could not be applied in 28% of our cases. This figure is some-what higher than reported by other authors<sup>25,33</sup> and could be explained by differences in ventilatory and inflammatory patterns. The cut-off point of normality was set at the upper limit calculated for the group of healthy children in our population (4.5 ppb),<sup>25</sup> which is similar to that described by other authors<sup>33,34</sup> who have used the same methodology. High concentrations of alveolar nitric

Table 4

Comparisons of the Various Parameters Indicating Small Airway Involvement in the Group of Asthmatic Children With Positive and Negative Bronchodilation Test.

|   | Neg | Negative BD Test         |    | Positive BD Test            |                  |
|---|-----|--------------------------|----|-----------------------------|------------------|
|   | n   | (Mean±SD)                | n  | (Mean±SD)                   |                  |
| CAno (ppb)                              | 59  | 1.22 (0–15) <sup>a</sup> | 13 | 3.30 (0.2–9.4) <sup>a</sup> | .00 <sup>c</sup> |
| R5-R20 (kPa/L/s)                        | 81  | 0.13±0.10                | 19 | 0.20±0.14                   | .01              |
| X5 (kPa/L)                              | 81  | $-0.18{\pm}0.09$         | 19 | $-0.24{\pm}0.09$            | .01              |
| FEF <sub>25-75</sub> ( <i>z</i> -score) | 81  | $-0.49{\pm}1.11$         | 19 | $-1.93{\pm}0.99$            | .00              |
| RV/TLC (%)                              | 81  | $27.88 {\pm} 6.25$       | 19 | $30.56 \pm 6.20$            | .09              |

BD: bronchodilation; CAno: alveolar concentration of nitric oxide; FEF<sub>25-75</sub>: forced expiratory flow between 25% and 75% of forced vital capacity; R5–R20: resistance between 5 and 20 Hz; RV/TLC: residual volume/total lung capacity ratio; SD: standard deviation; X5: resistance at 5 Hz; *z*-score: standardized variable to compare data.

<sup>a</sup> Median (range).

<sup>b</sup> Analysis using Student's *t* test.

<sup>c</sup> Analysis using Kruskal-Wallis test.

| 212   |   |
|-------|---|
| Tabla | 5 |

| 1 | aDic |       |
|---|------|-------|
| • |      | \$7.1 |

Mean Values of the Various Parameters Indicating Small Airway Involvement in the Overall Group of Children With Good and Poor Asthma Control.

|                                | Good Control |                          | Poor Control |                             | $p^{\mathrm{b}}$  |
|--------------------------------|--------------|--------------------------|--------------|-----------------------------|-------------------|
|                                | n            | (Mean±SD)                | n            | (Mean±SD)                   |                   |
| CAno (ppb)                     | 48           | 1.45 (0–15) <sup>a</sup> | 24           | 1.41 (0.1–9.4) <sup>a</sup> | 0.89 <sup>c</sup> |
| R5-R20 (kPa/L/s)               | 71           | 0.13±0.11                | 29           | 0.15±0.11                   | 0.49              |
| X5 (kPa/L)                     | 71           | $-0.18{\pm}0.09$         | 29           | $-0.21{\pm}0.08$            | 0.10              |
| FEF <sub>25-75</sub> (z-score) | 71           | $-0.76 \pm 1.11$         | 29           | $-0.77 \pm 1.48$            | 0.99              |
| RV/TLC (%)                     | 71           | 28.24±6.34               | 29           | 28.73±6.27                  | 0.72              |

CAno: alveolar concentration of nitric oxide; FEF25-75: forced expiratory flow between 25% and 75% of forced vital capacity; R5–R20: resistance between 5 and 20 Hz; RV/TLC: residual volume/total lung capacity ratio; SD: standard deviation; X5: resistance at 5 Hz; z-score: standardized variable to compare data.

<sup>a</sup> Median (range).

<sup>b</sup> Analysis using Student's *t* test.

<sup>c</sup> Analysis using Kruskal-Wallis test.

oxide were not detected in our study, which does not rule out inflammatory involvement of the SA, since both CAno levels and bronchial oxide concentration can be affected by the use of inhaled glucocorticoids.<sup>35</sup> Similarly to van Veen et al.,<sup>36</sup> we found no differences in CAno among the groups with moderate asthma and severe asthma.

SA evaluation using PO showed significantly higher values of R5–R20 in the group of children with severe as thma  $(0.19\pm0.14 \text{ Hz})$ , a result consistent with previous publications that report SA dysfunction in severe asthma.<sup>37</sup> No studies have been performed on dependent PO variables in the pediatric population to determine the cut-off point for SA involvement. For this reason, we used the cut-off points determined by Shi et al.<sup>4</sup> in a study performed to determine the usefulness of PO in disease control in asthmatic children, with the limitations that this implies. With these parameters, almost half of the cohort studied showed an increase in peripheral airway resistance and reduced reactance, suggesting that while these cut-off points are very sensitive for detecting SA changes, they are not useful for discriminating between moderate and severe asthma or well and poorly controlled asthma.

The use of FEF<sub>25-75</sub> for the study of SA is controversial, because of the dependence of this parameter on FVC and its low reproducibility.<sup>38</sup> Our study cohort showed a mean z-score of  $-0.76\pm1.22$  that is far from pathological, and no differences were observed between groups of different severity, probably due to the wide variability of this parameter. We selected a FEF<sub>25-75</sub> cutoff point on the basis of a study carried out in 700 children with asthma designed to define the cut-off point of this parameter.<sup>26</sup> We then calculated the z-score for our sample. In the analysis performed with this cut-off point, FEF<sub>25-75</sub> was the only SA parameter that showed a greater frequency and proportion in the group with severe asthma (P=.04). Although FEF<sub>25-75</sub> is the most accessible parameter in clinical practice, it should be interpreted with caution because of the limitations discussed previously.

We, like Sorkness et al.,<sup>39</sup> chose the RV/TLC ratio as an index of hyperinflation (air trapping). In order to identify hyperinflation with a high level of confidence, we defined the cut-off value as the 95th percentile of RV/TLC in children, which is 0.33.<sup>27</sup> In our study, mean RV/TLC was 28.38%±6.29%, and no significant differences were observed between the groups with moderate asthma and severe asthma. In our series, 20% of children had RV/TLC higher than 33%, compared to 7-11% detected by Mahut et al.,<sup>40</sup> probably because those cases had less severe asthma.

A total of 19 cases had a positive BD test. These patients had poorer results in SA markers than patients with negative BD results, so we can conclude that some degree of proximal airway obstruction does not confound SA analysis. In the group of children with positive BD test, the dependent variables of post-BD SA on PO, spirometry and plethysmography were analyzed, and a significant improvement in all indicators of SA involvement was observed.

We analyzed the usefulness of the SA study for defining the degree of disease control, and found that none of the variables related to SA showed any association with the degree of asthma control. Similarly, the sum of the different abnormal parameters was not associated with worse disease control. This result is in line with a study in adults with moderate or severe asthma<sup>12</sup> and normal proximal airways, in which no association was found between the ACT questionnaire score and the different SA parameters in the 222 patients studied. c-ACT and ACT appear to correlate well with the GINA criteria<sup>1</sup> for predicting the risk of uncontrolled asthma, but the cut-off points commonly used for c-ACT and ACT appear to underestimate the proportion of children with uncontrolled asthma as defined by GINA.<sup>41</sup> This might affect our results for the association between SA dysfunction and disease control. Another hypothesis to explain the lack of association between SA dysfunction and disease control could be that this is not a reason for poorer asthma control, but instead is a yet another feature of the disease, or else a phenomenon associated with other factors such as the allergic response,<sup>42</sup> or disease persistence, progress or prognosis.

The main limitation of our study is the absence of reference values to determine SA involvement. Moreover, the cross-sectional design makes it impossible to study the behavior of SA over time, in a disease in which variability over time is a defining characteristic. Similarly, the heterogeneity of severe asthma makes it difficult to study, because of the variability it can display depending on the time that studies are performed. Finally, the lack of technical guidelines for determining CAno should be taken into account. We therefore need longitudinal multicenter studies to clarify these and other doubts.

## Conclusions

Most children with moderate and severe asthma receiving treatment recommended for FEV1 within normal ranges have a dysfunctional SA phenotype in terms of resistance, reactance, inflammation, limitation of the peak expiratory flow or air trapping, with a moderate degree of agreement between them. This SA dysfunction is not related to the level of asthma control.

#### Funding

This research project has not received any funding.

#### **Conflict of Interests**

The authors state that they have no conflict of interests.

## Acknowledgements

We thank José I. Emparanza, MD, PhD, Clinical Research Unit of the Hospital Universitario de Donostia for performing the statistical analysis.

## References

- 1. Global initiative for asthma. Global strategy for asthma management and prevention. Updated 2016. Available from: http://ginasthma. org/2016-gina-report-global-strategy-for-asthma-management-andprevention/ [accessed 2.7.18].
- Ramos-Barbón D, Parra-Arrondo A. Inflamación y remodelación de la vía aérea pequeña: estudios en humanos y modelos experimentales. Arch Bronconeumol. 2011;47 Supl 2:2–9.
- Paull K, Covar R, Jain N, Gelfand E, Spahhn J. Do NHLBI lung function criteria apply to children? A cross-sectional evaluation of childhood asthma at National Jewish Medical and Research Center, 1999–2002. Pediatr Pulmonol. 2005;39: 311–7.
- Shi Y, Aledia AS, Tatavoosian AV, Vijayalakshmi S, Galant SP, George SC. Relating small airways to asthma control by using impulse oscillometry in children. J Allergy Clin Immunol. 2012;129:671–8.
- Heijkenskjöld Rentzhog C, Janson C, Berglund L, Borres MP, Nordvall L, Alving K, et al. Overall and peripheral lung function assessment by spirometry and forced oscillation technique in relation to asthma diagnosis and control. Clin Exp Allergy. 2017;47:1546–54.
- Manoharan A, Anderson W, Lipworth J, Ibrahim I, Lipworth B. Small airways dysfunction is associated with poorer control in asthmatics with a preserved FEV1. ERS. 2014;44 Suppl 58:3406.
- Siroux V, Boudier A, Dolgopoloff M, Chanoine S, Bousquet J, Gormand F, Just J, et al. Forced midexpiratory flow between 25% and 75% of forced vital capacity is associated with long-term persistence of asthma and poor asthma outcomes. J Allergy Clin Immunol. 2016;137:1709–16.
- Mahut B, Peiffer C, Bokov P, Beydon N, Delclaux C. Gas trapping is associated with severe exacerbation in asthmatic children. Respir Med. 2010;104:1230–3.
- 9. Svenningsen S, Nair P, Guo F, McCormack DG, Parraga G. Is ventilation heterogeneity related to asthma control? Eur Respir J. 2016:393.
- Busacker A, Newell JD Jr, Keefe T, Hoffman EA, Granroth JC, Castro M, et al. A multivariate analysis of risk factors for the air-trapping asthmatic phenotype as measured by quantitative CT analysis. Chest. 2009;135:48–56.
- 11. Mahut B, Delacourt C, Zerah-Lancner F, de Blic J, Harf A, Delclaux C. Increase in alveolar nitric oxide in the presence of symptoms in childhood asthma. Chest. 2004;125:1012–8.
- Perez T, Chanez P, Dusser D, Devillier P. Small airway impairment in moderate to severe asthmatics without significant proximal airway obstruction. Respir Med. 2013;107:1667–74.
- Singhania A, Rupani H, Jayasekera N, Lumb S, Hales P, Gozzard N, et al. Altered epithelial gene expression in peripheral airways of severe asthma. PLoS ONE. 2017;12:e0168680.
- Boulet LP, Vervloet D, Magar Y, Foster JM. Adherence: the goal to control asthma. Clin Chest Med. 2012;33:785–95.
- Tsoukias NM, George SC. A two-compartment model of pulmonary nitric oxide exchange dynamics. J Appl Physiol. 1998;85:653–66.
- American Thoracic Society; European Respiratory Society. ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005. Am J Respir Crit Care Med. 2005;171:912–30.
- Beydon N, Davis SD, Lombardi E, Allen JL, Arets H, Aurora P, et al. An official American Thoracic Society/European Respiratory Society statement: pulmonary function testing in preschool children. Am J Respir Crit Care Med. 2007;175:1304–45.
- Miller MR, Hankinson V, Brusasco RO, Burgos R, Casaburi A, Coates R, et al. Standardisation of spirometry ATS/ERS Task Force: standardisation of lung function testing. Eur Respir J. 2005;26:319–38.
- Wanger J, Clausen JL, Coates A, Pedersen OF, Brusasco V, Burgos F, et al. Standardisation of the measurement of lung volumes. Eur Respir J. 2005;26: 511–22.

- Horváth I, Barnes PJ, Loukides S, Sterk PJ, Högman M, Olin AC, et al. A European Respiratory Society technical standard: exhaled biomarkers in lung disease. Eur Respir J. 2017;49:1600965.
- Lechtenbörger P, Lechtenbörger S, Smith H, Steinkamp G, Berdel D. Resistance and reactance measured by impulse oscillometry: paediatric reference values in 614 healthy children and adolescents aged 5 to 17 years. Würzburg, Germany: Jaeger; 2003.
- 22. Jaeger M, Otis A. Measurement of airway resistance with a volume displacement body plethysmograph. J Appl Physiol. 1964;19:813–20.
- Zapletal A, Samanek M, Tuma S, Ruth C, Paul T. Assessment of airway function in children. Bull Physiopathol Respir. 1972;8:535–44.
- 24. Eliasson O, Degraff AC Jr. The use of criteria for reversibility and obstruction to define patient groups for bronchodilator trials Influence of clinical diagnosis, spirometric, and anthropometric variables. Am Rev Respir Dis. 1985;132:858–64.
- Sardón O, Corcuera P, Aldasoro A, Korta J, Mintegui J, Emparanza JI, et al. Alveolar nitric oxide and its role in pediatric asthma control assessment. BMC Pulm Med. 2014;14:126.
- 26. Ciprandi G, Capasso M, Tosca M, Salpietro C, Salpietro A, Marseglia G, et al. A forced expiratory flow at 25–75% value <65% of predicted should be considered abnormal: a real-world, cross-sectional study. Allergy Asthma Proc. 2012;33:e5–8.
- Stocks J, Quanjer PH. Reference values for residual volume, functional residual capacity and total lung capacity. ATS Workshop on Lung Volume Measurements. Official statement of the European Respiratory Society. Eur Respir J. 1995;8:492–506.
- Vega JM, Badia X, Badiola C, López-Viña A, Olaguíbel JM, Picado C, et al. Validation of the Spanish version of the Asthma Control Test (ACT). J Asthma. 2007;44:867–72.
- 29. Pérez-Yarza EG, Castro JA, Villa JR, Garde J, Hidalgo J, on behalf of the VESCASI Group. Validation of a Spanish version of the Childhood Asthma Control Test (Sc-ACT) for use in Spain. An Pediatr (Barc). 2015;83:94–103.
- 30. Pisi R, Tzani P, Aiello M, Martinelli E, Marangio E, Nicolini G, et al. Small airway dysfunction by impulse oscillometry in asthmatic patients with normal forced expiratory volume in the 1st second values. Allergy Asthma Proc. 2013;34:e14–20.
- Wagner EM, Liu MC, Weinmann GG, Permutt S, Bleecker ER. Peripheral lung resistance in normal and asthmatic subjects. Am Rev Respir Dis. 1990;141:584.
- Torrego Fernández A, Muñoz Cano RM. Importancia clínica de la afectación de la vía aérea pequeña en el asma. Arch Bronconeumol. 2011;47 Supl 2:17–9.
- Puckett JL, Taylor RW, Leu SY, Guijon OL, Aledia AS, Galant SP, et al. Clinical patterns in asthma based on proximal and distal airway nitric oxide categories. Respir Res. 2010;11:47.
- Sepponen A, Lehtimäki L, Huhtala H, Kaila M, Kankaanranta H, Moilanen E. Alveolar and bronchial nitric oxide output in healthy children. Pediatr Pulmonol. 2008;43:1242–8.
- Michils A, Baldassarre S, van Muylem A. Exhaled nitric oxide and asthma control: a longitudinal study in unselected patients. Eur Respir J. 2008;31:539–46.
- Van Veen IH, Sterk PJ, Schot R, Gauw SA, Rabe KF, Bel EH. Alveolar nitric oxide versus measures of peripheral airway dysfunction in severe asthma. Eur Respir J. 2006;27:951–6.
- 37. Umar I, Desai D, Corkill S, Shelley M, Singapuri A, Brightling C, et al. Impulse oscillometry (IOS) indices in severe asthma and healthy controls after deep breath manoeuvres and bronchodilator administration. Thorax. 2010;65 Suppl 4:A129–30.
- Quanjer PH, Weiner DJ, Pretto JJ, Brazzale DJ, Boros PW. Measurement of FEF25–75% and FEF75% does not contribute to clinical decision making. Eur Respir J. 2014;43:1051–8.
- Sorkness RL, Bleecker ER, Busse WW, Calhoun WJ, Castro M, Chung KF, et al. Lung function in adults with stable but severe asthma: air trapping and incomplete reversal of obstruction with bronchodilation. J Appl Physiol. 2008;104:394–403.
- Mahut B, Bokov P, Delclaux C. Abnormalities of plethysmographic lung volumes in asthmatic children. Respir Med. 2010;104:966–71.
- Koolen B, Pijnenburg M, Brackel H, Landstra A, van den Berg N, Merkuse P, et al. Comparing Global Initiative for Asthma (GINA) criteria with the Childhood Asthma Control Test (C-ACT) and Asthma Control Test (ACT). Eur Respir J. 2011;38:561–6.
- 42. Stenberg H, Diamant Z, Ankerst J, Bjermer L, Tufvesson E. Small airway involvement in the late allergic response in asthma. Clin Exp Allergy. 2017;47:1555–65.